First Berlin – Pharming Group NV Research Update (18/01/2018)

First Berlin Equity Research has published a research update on Pharming Group NV (ISIN: NL0010391025). Analyst Simon Scholes reiterated his BUY rating and increased the price target from EUR 1.70 to EUR 1.90.

Abstract
The FDA has stated that it will issue a verdict on the approval of Ruconest for prophylaxis of hereditary angioedema (HAE) by 21 September. Following this news, we are bringing forward our forecast for the timing of first post-approval revenues in prophylaxis from 2019 to Q4 2018. We also lower our discount rate for future prophylaxis revenues to reflect the increased probability of approval. We now see fair value for the share at €1.90 (previously: €1.70). We maintain our Buy recommendation.